Overview

* Supernus Q2 2025 total revenue dips 2% yr/yr to $165.5 mln

* Adjusted revenue excluding Trokendi XR, Oxtellar XR rises 17% yr/yr

* Co completes Sage Therapeutics acquisition, enhancing neuropsychiatric portfolio

Outlook

* Supernus raises 2025 revenue guidance to $670 mln - $700 mln

* Company expects 2025 operating loss between $70 mln - $80 mln

* Supernus expects adjusted operating earnings of $105 mln - $135 mln in 2025

Result Drivers

* QELBREE SALES - Qelbree net sales rose 31% in Q2 2025

* GOCOVRI SALES - GOCOVRI net sales increased 16% in Q2 2025, contributing to overall revenue

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 $158 mln

Product

Sales

Q2 $142.70

Adjusted mln

Revenue

Q2 $12.14

Operatin mln

g

Earnings

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Supernus Pharmaceuticals Inc ( SUPN ) is $40.00, about 7.4% above its August 4 closing price of $37.05

* The stock recently traded at 18 times the next 12-month earnings vs. a P/E of 15 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)